Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascula…
| Métrica | NVO | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | 81.0% | 57.4% | +23.6% |
| Operating Margin | 41.3% | -34.4% | +75.7% |
| Net Margin | 33.1% | -32.5% | +65.6% |
| FCF Margin | 19.1% | -12.6% | +31.7% |
| ROE | 52.8% | -39.2% | +92.0% |
| ROA | 18.9% | -30.9% | +49.8% |
| Current Ratio | 0.80 | 2.73 | -1.93 |
| Debt / Equity | 0.61 | 0.28 | +0.33 |
| Calidad del negocio | FY25 |
|---|---|
| ✓Margen FCF > 10 % | 19.1% |
| ✓ROCE > 10 % | 39.0% |
| ✓Ventas > 5 %/año (3 años) | 20.4% |
| ✓Deuda neta/EBITDA < 3x | 0.7x |
| ✓Reinversión (I+D + capex) > 3 % de ventas | 36.3% |
NOVO NORDISK A S cotiza a 38.83 USD y tiene una capitalización bursátil de $171.4B. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud